featured
2020 Top Stories in Oncology: Supportive Care
Written by
Written by
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782-2797.
- Vieira C, Fragoso M, Pereira D, Medeiros R. Pain prevalence and treatment in patients with metastatic bone disease. Oncol Lett. 2019;17(3):3362-3370.
- Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1650-1663.
- Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199-3212.
- Klastersky J, De Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118
- NCCN. Clinical Practice Guidelines in Oncology. Hematopoietic growth factors, version 2.2020. Accessed December 1, 2020.
- Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol/Hematol. 2014;90(3):190-199.
- Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014(10):CD003039.
- Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158-3167.
- Crawford J, Becker PS, Armitage JO, et al. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(12):1520-1541.
- Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199-3212.
- Pegfilgrastim. Prescribing information. Amgen; 2015. Accessed December 1, 2020.
- Pegfilgrastim-jmdb. Prescribing information. Mylan; 2018. Accessed December 1, 2020.
- Pegfilgrastim-cbqv. Prescribing information. Coherus BioSciences; 2018. Accessed December 1, 2020.
- Schwartzberg LS, Lal LS, Balu S, et al. Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy. J Manag Care Spec Pharm. 2018;24(10):976-984.
- Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. Int J Clin Transfus. 2018;6:21.
- Gascón P, Nagarkar R, Šmakal M, et al. A randomized, double-blind, placebo-controlled, phase III noninferiority study of the long-term safety and efficacy of darbepoetin alfa for chemotherapy-induced anemia in patients with advanced NSCLC. J Thorac Oncol. 2020;15(2):190-202.
- Leyland-Jones B, Bondarenko I, Nemsadze G, et al. A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J Clin Oncol. 2016;34(11):1197-1207.
- Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(suppl 4):iv96-iv110.